We begin this episode by discussing our article of the week from the Lancet “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA”.
In the second half of our episode, we begin with a discussion of Wegovy and the latest data on its human use. Next, we discuss congenital heart disease in sports. Following that, we examine the latest developments with the COVID-19 virus, and last but not least, we examine the recent news about long-lasting chemicals found in paper straws, and their impact on human health.
